share_log

424B5: Prospectus

SEC announcement ·  Jul 22 23:27
Summary by Futu AI
60 Degrees Pharmaceuticals, Inc. has updated its prospectus supplement on July 22, 2024, to reflect an increase in the maximum aggregate gross sales price of its common stock offered through an At the Market Issuance Sales Agreement with WallachBeth Capital LLC. The increase adjusts the sales cap from the previously registered $1,253,603 to $1,774,640. As of the filing date, 3,969,076 shares have been sold under the agreement, amounting to an aggregate gross sales price of $1,197,073.32. The company's common stock is traded on The Nasdaq Capital Market under the symbol 'SXTP', with a closing sale price of $0.271 per share on July 19, 2024. The ATM Offering terms remain unchanged, and the Sales Agreement is still in effect. The company's market value of outstanding common stock held by non-affiliates is approximately $5,154,331, based on a share price of $0.351 as of June 7, 2024. The company has emphasized the significant risks associated with investing in its common stock, as detailed in the 'Risk Factors' section of the Prospectus Supplement and Base Prospectus, and other SEC filings.
60 Degrees Pharmaceuticals, Inc. has updated its prospectus supplement on July 22, 2024, to reflect an increase in the maximum aggregate gross sales price of its common stock offered through an At the Market Issuance Sales Agreement with WallachBeth Capital LLC. The increase adjusts the sales cap from the previously registered $1,253,603 to $1,774,640. As of the filing date, 3,969,076 shares have been sold under the agreement, amounting to an aggregate gross sales price of $1,197,073.32. The company's common stock is traded on The Nasdaq Capital Market under the symbol 'SXTP', with a closing sale price of $0.271 per share on July 19, 2024. The ATM Offering terms remain unchanged, and the Sales Agreement is still in effect. The company's market value of outstanding common stock held by non-affiliates is approximately $5,154,331, based on a share price of $0.351 as of June 7, 2024. The company has emphasized the significant risks associated with investing in its common stock, as detailed in the 'Risk Factors' section of the Prospectus Supplement and Base Prospectus, and other SEC filings.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.